NovoCure Limited (NVCR) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$10.56M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$67.42M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$36.02M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$39.52M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$10.56M | (m) | (m) | (m) | $6.92M | $8.13M | (m) | $51.45M | (m) | $3.21M |
| 2026-03-31 | Reported | (m) | -$67.42M | (m) | (m) | (m) | $5.15M | -$13.52M | (m) | $58.34M | (m) | $1.88M |
| 2025-09-30 | Reported | (m) | -$36.02M | (m) | (m) | (m) | $5.66M | $20.57M | (m) | $54.03M | (m) | $7.25M |
| 2025-06-30 | Reported | (m) | -$39.52M | (m) | (m) | (m) | $5.49M | -$15.94M | (m) | $55.83M | (m) | $5.16M |
| 2025-03-31 | Reported | (m) | -$37.87M | (m) | (m) | (m) | $10.61M | -$35.66M | (m) | $53.78M | (m) | $4.02M |
| 2024-09-30 | Reported | (m) | -$32.09M | (m) | (m) | (m) | $10.68M | $10.38M | (m) | $51.88M | (m) | $8.98M |
| 2024-06-30 | Reported | (m) | -$33.58M | (m) | (m) | (m) | $11.45M | -$1.72M | (m) | $54.95M | (m) | $10.65M |
| 2024-03-31 | Reported | (m) | -$41.52M | (m) | (m) | (m) | $11.78M | -$31.57M | (m) | $51.60M | (m) | $7.12M |
| 2023-09-30 | Reported | (m) | -$58.24M | (m) | (m) | (m) | $7.25M | -$19.31M | (m) | $53.62M | (m) | $1.26M |
| 2023-06-30 | Reported | (m) | -$62.66M | (m) | (m) | (m) | $6.93M | -$22.74M | (m) | $55.43M | (m) | $3.51M |
| 2023-03-31 | Reported | (m) | -$60.25M | (m) | (m) | (m) | $6.09M | -$16.73M | (m) | $59.70M | (m) | $1.98M |
| 2022-12-31 | Reported | (m) | -$42.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$24.61M | (m) | (m) | (m) | $5.70M | $22.42M | (m) | $51.96M | (m) | $3.16M |
| 2022-06-30 | Reported | (m) | -$21.13M | (m) | (m) | (m) | $4.13M | $15.76M | (m) | $57.08M | (m) | $652.00K |
| 2022-03-31 | Reported | (m) | -$806.00K | (m) | (m) | (m) | $5.09M | -$3.69M | (m) | $42.23M | (m) | $2.13M |
| 2021-12-31 | Reported | (m) | -$23.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$8.55M | (m) | (m) | (m) | $3.30M | $24.40M | (m) | $48.14M | (m) | $2.59M |
| 2021-06-30 | Reported | (m) | -$12.29M | (m) | (m) | (m) | $2.62M | $26.17M | (m) | $50.31M | (m) | $1.41M |
| 2021-03-31 | Reported | (m) | -$88.00K | (m) | (m) | (m) | $3.98M | $17.78M | (m) | $45.92M | (m) | $1.39M |
| 2020-12-31 | Reported | (m) | $12.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | Reported | (m) | $15.02M | (m) | (m) | (m) | $2.78M | $30.97M | (m) | $32.82M | (m) | $1.75M |
| 2020-06-30 | Reported | (m) | $6.67M | (m) | (m) | (m) | $3.31M | $12.74M | (m) | $29.92M | (m) | $2.40M |
| 2020-03-31 | Reported | (m) | -$3.38M | (m) | (m) | (m) | $3.11M | $1.96M | (m) | $25.27M | (m) | -$9.77M |
| 2019-12-31 | Reported | (m) | $153.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | Reported | (m) | $3.85M | (m) | (m) | (m) | $2.71M | $14.91M | (m) | $18.77M | (m) | -$630.00K |
| 2019-06-30 | Reported | (m) | $1.20M | (m) | (m) | (m) | $2.40M | $9.07M | (m) | $19.45M | (m) | $1.23M |
| 2019-03-31 | Reported | (m) | -$6.12M | (m) | (m) | (m) | $2.33M | -$4.32M | (m) | $17.04M | (m) | $3.66M |
| 2018-12-31 | Reported | (m) | -$8.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$5.25M | (m) | (m) | (m) | $1.35M | $5.64M | (m) | $13.07M | (m) | $4.05M |
| 2018-06-30 | Reported | (m) | -$7.08M | (m) | (m) | (m) | $854.00K | -$7.49M | (m) | $11.36M | (m) | $5.57M |
| 2018-03-31 | Reported | (m) | -$12.68M | (m) | (m) | (m) | $737.00K | -$16.82M | (m) | $11.10M | (m) | $3.19M |
| 2017-12-31 | Reported | (m) | -$4.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$5.92M | (m) | (m) | (m) | $544.00K | $2.55M | (m) | $9.27M | (m) | $3.42M |
| 2017-06-30 | Reported | (m) | -$15.53M | (m) | (m) | (m) | $376.00K | -$5.88M | (m) | $9.37M | (m) | $3.46M |
| 2017-03-31 | Reported | (m) | -$13.37M | (m) | (m) | (m) | $1.03M | (m) | (m) | $9.41M | (m) | $2.23M |
| 2016-12-31 | Reported | (m) | -$17.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$28.27M | (m) | (m) | (m) | $1.72M | (m) | (m) | $10.23M | (m) | $3.17M |
| 2016-06-30 | Reported | (m) | -$37.24M | (m) | (m) | (m) | $2.34M | (m) | (m) | $11.32M | (m) | $2.82M |
| 2016-03-31 | Reported | (m) | -$31.94M | (m) | (m) | (m) | $1.00M | (m) | (m) | $11.45M | (m) | $2.95M |
| 2015-12-31 | Reported | (m) | -$30.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$24.24M | (m) | (m) | (m) | $1.20M | (m) | (m) | $10.21M | (m) | $976.00K |
| 2015-06-30 | Reported | (m) | -$27.21M | (m) | (m) | (m) | $1.81M | (m) | (m) | $12.77M | (m) | $1.27M |
| 2015-03-31 | Reported | (m) | -$21.95M | (m) | (m) | (m) | $609.00K | (m) | (m) | $9.93M | (m) | $736.00K |
| 2014-09-30 | Reported | (m) | -$17.91M | (m) | (m) | (m) | (m) | (m) | (m) | $9.28M | (m) | $362.00K |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$153.80M | (m) | (m) | (m) | $26.65M | -$49.03M | (m) | $224.54M | (m) | -$23.00K |
| 2024-12-31 | Reported | (m) | -$170.50M | (m) | (m) | (m) | $42.85M | -$26.37M | (m) | $209.65M | (m) | $37.47M |
| 2023-12-31 | Reported | (m) | -$232.87M | (m) | (m) | (m) | $27.09M | -$73.34M | (m) | $223.06M | (m) | $15.30M |
| 2023-09-30 | Rolling | (m) | -$224.13M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | Rolling | (m) | -$190.50M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | Rolling | (m) | -$148.97M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$89.52M | (m) | (m) | (m) | $21.36M | $30.79M | (m) | $206.09M | (m) | $10.69M |
| 2022-12-31 | Rolling | (m) | -$89.52M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | Rolling | (m) | -$69.94M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | Rolling | (m) | -$53.88M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | Rolling | (m) | -$45.05M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$44.33M | (m) | (m) | (m) | $24.17M | $82.76M | (m) | $201.30M | (m) | $6.28M |
| 2021-12-31 | Rolling | (m) | -$44.33M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | Rolling | (m) | -$8.84M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | Rolling | (m) | $14.73M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | Rolling | (m) | $33.69M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | Reported | (m) | $30.40M | (m) | (m) | (m) | $14.97M | $99.15M | (m) | $132.01M | (m) | -$1.71M |
| 2020-12-31 | Rolling | (m) | $30.40M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | Rolling | (m) | $18.46M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | Rolling | (m) | $7.29M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | Rolling | (m) | $1.82M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$914.00K | (m) | (m) | (m) | $10.48M | $26.62M | (m) | $79.00M | (m) | -$1.59M |
| 2019-12-31 | Rolling | (m) | -$914.00K* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | Rolling | (m) | -$9.73M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | Rolling | (m) | -$18.83M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | Rolling | (m) | -$27.11M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$33.67M | (m) | (m) | (m) | $6.71M | -$1.86M | (m) | $50.57M | (m) | $17.62M |
| 2018-12-31 | Rolling | (m) | -$33.67M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Rolling | (m) | -$29.51M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | Rolling | (m) | -$30.19M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | Rolling | (m) | -$38.63M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$39.33M | (m) | (m) | (m) | $7.37M | -$33.13M | (m) | $38.10M | (m) | $13.16M |
| 2017-12-31 | Rolling | (m) | -$39.33M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | Rolling | (m) | -$52.70M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | Rolling | (m) | -$75.05M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | Rolling | (m) | -$96.75M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$115.32M | (m) | (m) | (m) | $5.67M | -$107.59M | (m) | $41.47M | (m) | $10.38M |
| 2016-12-31 | Rolling | (m) | -$115.32M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | Rolling | (m) | -$128.05M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | Rolling | (m) | -$124.02M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | Rolling | (m) | -$113.99M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$104.00M | (m) | (m) | (m) | $4.67M | (m) | (m) | $43.75M | (m) | $4.43M |
| 2015-12-31 | Rolling | (m) | -$104.00M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$80.16M | (m) | (m) | (m) | $849.00K | (m) | (m) | $40.38M | (m) | $382.00K |
| 2013-12-31 | Reported | (m) | -$64.46M | (m) | (m) | (m) | $2.20M | (m) | (m) | $34.80M | (m) | $353.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |